참고문헌
- Al Mamari S, Djordjevic J, Halliday JS, et al (2013). Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol, 58, 329-34. https://doi.org/10.1016/j.jhep.2012.10.013
- Bhudhisawasdi V, Khuntikeo N, Chur-in S, et al (2012). Cholangiocarcinoma: experience of Srinagarind hospital. Srinagarind Med J, 27, 331-9.
- Blechacz BR, Gores GJ (2008). Cholangiocarcinoma. Clin Liver Dis, 12, 131-50. https://doi.org/10.1016/j.cld.2007.11.003
- Braconi C, Patel T (2010). Cholangiocarcinoma: new insights into disease pathogenesis and biology. Infect Dis Clin North Am, 24, 871-84. https://doi.org/10.1016/j.idc.2010.07.006
- Changbumrung S, Tungtrongchitr R, Migasena P, et al (1990). Serum unconjugated primary and secondary bile acids in patients with cholangiocarcinoma and hepatocellular carcinoma. J Med Assoc Thai, 73, 81-90.
- Fausa O, Gjone E (1976). Serum bile acid concentrations in patients with liver disease. Scand J Gastroenterol, 11, 537-43.
- Heaton KW (1979). Bile salt tests in clinical practice. Br Med J, 1, 644-6. https://doi.org/10.1136/bmj.1.6164.644
- Jusakul A, Khuntikeo N, Haigh WG, et al (2012). Identification of biliary bile acids in patients with benign biliary diseases, hepatocellular carcinoma and cholangiocarcinoma. Asian Pac J Cancer Prev, 13, 77-82.
- Motawa E. El- Houseine, Mahmoud A. Amer, Abdel Hakim Saad El-Din, et al (2000). Evaluation of serum total bile acids in the diagnosis of hepatocellular carcinoma. J Egypt Natl Cancer Inst, 12, 307-13.
- Shaffer EA, Gordon ER (1978). Serum bile acids as related to bile acid secretion in liver disease. Am J Dig Dis, 23, 392-7. https://doi.org/10.1007/BF01072920
- Sripa B, Bethony JM, Sithithaworn P, et al (2011). Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in Thailand and Laos. Acta Trop, 120, 158-68. https://doi.org/10.1016/j.actatropica.2010.07.006
- Sripa B, Kaewkes S, Sithithaworn P, et al (2007). Liver fluke induces cholangiocarcinoma. PLoS Med, 4, 201. https://doi.org/10.1371/journal.pmed.0040201
- Stanich PP, Bjornsson E, Gossard AA, et al (2011). Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis, 43, 309-13. https://doi.org/10.1016/j.dld.2010.12.008
- Sugiyama M, Atomi Y, Kuroda A, et al (1997). Bile duct carcinoma without jaundice: clues to early diagnosis. Hepatogastroenterology, 44, 1477-83.
- Tabibian N (1988). Serum bile acid levels in liver disease: is there a clinical application? South Med J, 81, 281-2. https://doi.org/10.1097/00007611-198802000-00036
- Webster CR, Usechak P, Anwer MS (2002). cAMP inhibits bile acidinduced apoptosis by blocking caspase activation and cytochrome c release. Am J Physiol Gastrointest Liver Physiol, 283, 727-38. https://doi.org/10.1152/ajpgi.00410.2001
- Wiangnon S, Suwanrungruang K, Kamsa-Ard S (2012). Cholangiocarcinoma in Khon Kaen Province. Srinagarind Med J, 27, 326-30.
- Wongkham S, Silsirivanit A (2012). State of serum markers for detection of cholangiocarcinoma. Asian Pac J Cancer Prev, 13 Suppl, 17-27.
- Zografos GN, Farfaras A, Zagouri F, et al (2011). Cholangiocarcinoma: principles and current trends. Hepatobiliary Pancreat Dis Int, 10, 10-20. https://doi.org/10.1016/S1499-3872(11)60001-5
피인용 문헌
- Development of an enzyme-linked immunosorbent assay for chenodeoxycholic acid using an anti-chenodeoxycholic acid monoclonal antibody vol.7, pp.11, 2015, https://doi.org/10.1039/C5AY00733J
- Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis pp.02709139, 2019, https://doi.org/10.1002/hep.30319